ABSTRACT

Objective

This meta-analysis aims to explore the diagnostic value and accuracy of circulating lncRNAs as biomarkers of digestive system tumors.

Methods

PubMed, Embase, Cochrane Library, and Web of science were searched for relevant articles that were published before April 2019, and a meta-analysis was conducted.

Results

52 studies with 63 lncRNAs were discussed in the meta-analysis. The pooled sensitivity and specificity of diagnosis were 0.80 (95% CI: 0.79–0.81) and 0.76 (95% CI: 0.75–0.77), respectively. The pooled DOR (the diagnostic odds ratio) was 15.63 (95% CI: 12.77–19.12), and the overall AUC (the area under the curve) was 0.87. Besides, subgroup analyzes showed that the DOR and AUC of large sample sizes (>80), multiple lncRNAs, serum-based lncRNAs, and downregulation group were superior to those of small sample sizes (≤80), single lncRNA, plasma-based lncRNAs, and upregulation group, respectively. The current data also highlight that the diagnostic accuracy of circulating lncRNAs in the case of colorectal cancer was higher than gastric cancer, hepatocellular carcinoma, esophageal carcinoma, and pancreatic cancer. And there is no difference in the perspective of geographical regions.

Conclusion

The circulating lncRNAs have high diagnostic value and accuracy in digestive system cancers and may serve as potential biomarkers.

中文翻译：

---

循环lncRNA作为消化系统癌症生物标志物的诊断价值：系统评价和荟萃分析

摘要

客观的

本荟萃分析旨在探讨循环lncRNA作为消化系统肿瘤生物标志物的诊断价值和准确性。

方法

检索了 PubMed、Embase、Cochrane Library 和 Web of science 2019 年 4 月之前发表的相关文章，并进行了荟萃分析。

结果

荟萃分析讨论了涉及 63 种 lncRNA 的 52 项研究。诊断的汇总敏感性和特异性分别为 0.80 (95% CI: 0.79–0.81) 和 0.76 (95% CI: 0.75–0.77)。汇总 DOR（诊断比值比）为 15.63（95% CI：12.77-19.12），总体 AUC（曲线下面积）为 0.87。此外，亚组分析显示，大样本量（>80）、多个lncRNA、基于血清的lncRNA和下调组的DOR和AUC优于小样本量（≤80）、单个lncRNA、基于血浆的lncRNA ，和上调组，分别。目前的数据还强调，循环lncRNA对结直肠癌的诊断准确性高于胃癌、肝细胞癌、食管癌和胰腺癌。而且从地理区域的角度来看也没有差异。

结论

循环lncRNA对消化系统癌症具有较高的诊断价值和准确性，可作为潜在的生物标志物。